MSB-7267

AMENDMENTS TO THE CLAIMS

1. (Cancelled)
2. (Cancelled)
3. (Cancelled)
4. (Cancelled)
5. (Cancelled)
6. (Cancelled)
7. (Cancelled)
8. (Cancelled)
9. (Cancelled)
10. (Cancelled)
11. (Cancelled)

~~12.~~ (Currently Amended) A stable lyophilized pharmaceutical composition comprising approximately 1 to 4 milligrams per milliliter of a ~~wild-type~~ human IL-2 mutein and a stabilizing mixture comprising histidine, glycine, and sucrose, wherein said human IL-2 mutein consists of the amino acid sequence of wild-type human IL-2 with one substitution consisting of the replacement of the amino acid asparagine at position 88 in the wild-type human IL-2 with the amino acid arginine.

~~13.~~ (Previously amended) The stable lyophilized composition of claim ~~12~~ 1, wherein the histidine is present at approximately 0.06 -1.8 % measured by weight.

~~14.~~ (Previously amended) The stable lyophilized composition of claim ~~12~~ 1, wherein the glycine is present at approximately 1-3 % measured by weight.

4 15. (Previously amended) The stable lyophilized composition of claim 12, wherein the sucrose is present at approximately 0.5-3 % measured by weight.

5 16. (Previously amended) The stable lyophilized composition of claim 12 in aqueous form having a pH ranging from about 5.0 to 6.5.

6 17. (Previously amended) A stable lyophilized pharmaceutical composition, which upon aqueous reconstitution comprises the following:

E1

1.0 - 4.0 mg/ml of a human IL-2 mutein consisting of the amino acid sequence of wild-type human IL-2 with one substitution consisting of the replacement of the amino acid asparagine at position 88 in the wild-type human IL-2 with the amino acid arginine,

and

T 0190

Histidine	0.08 -1.6 % wt,
NaCl	0 - 0.9 wt %
Sucrose	1 - 10 % wt, and
Glycine	0 - 3% wt at a
pH of	5 - 6.5 .

E